Skip to main content

Advertisement

SpringerLink
Log in

Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

THIOMAB™ drug conjugates (TDCs) with engineered cysteine residues allow site-specific drug conjugation and defined Drug-to-Antibody Ratios (DAR). In order to help elucidate the impact of drug-loading, conjugation site, and subsequent deconjugation on pharmacokinetics and efficacy, we have developed an integrated mathematical model to mechanistically characterize pharmacokinetic behavior and preclinical efficacy of MMAE conjugated TDCs with different DARs. General applicability of the model structure was evaluated with two different TDCs.

Method

Pharmacokinetics studies were conducted for unconjugated antibody and purified TDCs with DAR-1, 2 and 4 for trastuzumab TDC and Anti-STEAP1 TDC in mice. Total antibody concentrations and individual DAR fractions were measured. Efficacy studies were performed in tumor-bearing mice.

Results

An integrated model consisting of distinct DAR species (DAR0-4), each described by a two-compartment model was able to capture the experimental data well. Time series measurements of each Individual DAR species allowed for the incorporation of site-specific drug loss through deconjugation and the results suggest a higher deconjugation rate from heavy chain site HC-A114C than the light chain site LC-V205C. Total antibody concentrations showed multi-exponential decline, with a higher clearance associated with higher DAR species. The experimentally observed effects of TDC on tumor growth kinetics were successfully described by linking pharmacokinetic profiles to DAR-dependent killing of tumor cells.

Conclusion

Results from the integrated model evaluated with two different TDCs highlight the impact of DAR and site of conjugation on pharmacokinetics and efficacy. The model can be used to guide future drug optimization and in-vivo studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

REFERENCES

  1. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13:235–44.

    Article  CAS  PubMed  Google Scholar 

  2. Ballantyneand A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs. 2013;73:755–65.

    Article  Google Scholar 

  3. Singhand R, Erickson HK. Antibody-cytotoxic agent conjugates: preparation and characterization. Methods Mol Biol. 2009;525:445–67. xiv.

    Article  Google Scholar 

  4. Carterand PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154–69.

    Article  Google Scholar 

  5. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5:147–59.

    Article  CAS  PubMed  Google Scholar 

  6. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011;22:1994–2004.

    Article  CAS  PubMed  Google Scholar 

  7. Linand K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29:2354–66.

    Article  Google Scholar 

  8. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70.

    Article  CAS  PubMed  Google Scholar 

  9. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925–32.

    Article  CAS  PubMed  Google Scholar 

  10. Behrensand, CR, Liu B. Methods for site-specific drug conjugation to antibodies. MAbs. 2013; 6.

  11. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30:184–9.

    Article  CAS  PubMed  Google Scholar 

  12. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods. 2008;332:41–52.

    Article  CAS  PubMed  Google Scholar 

  13. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19:759–65.

    Article  CAS  PubMed  Google Scholar 

  14. Xu K, Liu L, Saad OM, Baudys J, Williams L, Leipold D, et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem. 2011;412:56–66.

    Article  CAS  PubMed  Google Scholar 

  15. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther. 2012;92:520–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39:643–59.

    Article  PubMed  Google Scholar 

  17. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–58.

    Article  CAS  PubMed  Google Scholar 

  18. Koch G, Walz A, Lahu G, Schropp J. Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn. 2009;36:179–97.

    Article  CAS  PubMed  Google Scholar 

  19. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64:1094–101.

    Article  CAS  PubMed  Google Scholar 

  20. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778–84.

    Article  CAS  PubMed  Google Scholar 

  21. Bhakta S, Raab H, Junutula JR. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers. Methods Mol Biol. 2013;1045:189–203.

    Article  PubMed  Google Scholar 

  22. King HD, Yurgaitis D, Willner D, Firestone RA, Yang MB, Lasch SJ, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjug Chem. 1999;10:279–88.

    Article  CAS  PubMed  Google Scholar 

Download references

ACKNOWLEDGMENTS AND DISCLOSURES

The authors would like to thank Paul J. Fielder and other PKPD colleagues for their constructive input to this work.

Author information

Authors and Affiliations

  1. Genentech Research and Early Development, 1 DNA Way, South San Francisco, California, 94080, USA

    Siddharth Sukumaran, Kapil Gadkar, Crystal Zhang, Sunil Bhakta, Luna Liu, Keyang Xu, Helga Raab, Shang-Fan Yu, Elaine Mai, Aimee Fourie-O’Donohue, Katherine R. Kozak, Saroja Ramanujan, Jagath R. Junutula & Kedan Lin

Authors
  1. Siddharth Sukumaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kapil Gadkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Crystal Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sunil Bhakta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luna Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keyang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helga Raab
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shang-Fan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elaine Mai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aimee Fourie-O’Donohue
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Katherine R. Kozak
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Saroja Ramanujan
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jagath R. Junutula
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kedan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kedan Lin.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 219 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sukumaran, S., Gadkar, K., Zhang, C. et al. Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates. Pharm Res 32, 1884–1893 (2015). https://doi.org/10.1007/s11095-014-1582-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-014-1582-1

KEY WORDS

Search

Navigation